I-CAN Biocollection

Intracranial Aneurysm Clinical Trial

— I-CAN  

Official title:

IntraCranial ANeurysms: From Familial Forms to Pathophysiological Mechanisms

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02712892
• Other study ID #: RC15_0304
• Status: Completed
• Start date: March 3, 2016
• Est. completion date: December 31, 2020

Study information

• Verified date: September 2021
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Intracranial aneurysm (IA) is an asymptomatic cerebrovascular abnormality affecting 3.2% of the general population. The devastating complication of IA is its rupture, resulting in subarachnoid haemorrhage that can lead to severe disability and death. Unfortunately, there are neither reliable clues nor diagnostic tools to predict the formation and/or the fate of an IA in a given individual. Also, there is no pharmacological drug available to prevent the rupture of aneurysm and subsequent subarachnoid haemorrhage. Current treatments are invasive with a significant risk of procedural morbidity. Thus, still now, the management of patients with IA remains extremely challenging and still controversial. Although the pathogenesis of IA has been the subject of many studies for the last decade, the mechanisms underlying IA formation, growth and rupture are still mostly unknown and relevant animal models of IA are not available. Familial history of IA predisposes to IA formation and rupture and increasing evidence suggest a genetic component of IA formation, with heterogeneous modes of inheritance and penetrance. This project, gathering neuroradiologists, geneticists and vascular biologists, addresses the urgent need to understand the pathogenic mechanisms of IA to develop diagnostic and predictive tools of risk of IA. The investigators propose to identify IA-causing variants by whole-exome sequencing in familial forms of the disease. The investigators hypothesises that the functional analysis of the causal/susceptibility variants thus identified will provide clues to understanding the pathological mechanisms of IA formation, and the bases for developing diagnostic tools. This project aims at meeting this challenge. Based on preliminary data that already allowed to identify such a variant, and the combination of genetic and functional investigations, the specific objectives of this project are: - To identify IA-causing variants in familial forms of the disease by whole-exome sequencing; - To understand the function of these genes/variants in the formation and rupture of IA by molecular and cellular approaches and generation of relevant animal models; - To discover potential biomarkers of risk of IA formation and/or rupture.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3078
• Est. completion date: December 31, 2020
• Est. primary completion date: December 19, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion criteria indexes and related cases (familial) of intracranial aneurysms:

• Index: Any patient consulting for a major IA and some typical bifurcation with at least one other case reached akin IA 1st degree
• Related: All similar to the first degree, aged 20 or more, patients with a family background of IA and some typical bifurcation (=2 achieved) For the latter, directed by screening with Magnetic resonance imaging (MRI) sequence Time of Flight (TOF), axial T2, EGT2.
• biocollection of Written Consent for participation in the collection of biological samples

Inclusion criteria sporadic cases of IA:

• Any patient consulting for IA and some typical bifurcation
• Patients aged 20 years or older
• biocollection of Written Consent for participation in the collection of biological samples

Non Inclusion Criteria:

• Patients who have shown the inability or refusal to sign the consent informed biocollection
• syndromic diagnosis known as AIC provider
• Marfan Syndrome
• AOS with SMAD 3
• Danlos Syndrome Elhers type II and IV
• Autosomal Dominant Polycystic
• Moyamoya Syndrome
• character of IA:
• Dissecting or fusiform
• Combined with an arteriovenous malformation
• Blister-like
• mycotic
• Pathology of the cerebral white matter detected on MRI suggestive:
• Mutation COL4A1

Related Conditions & MeSH terms

• Aneurysm
• Intracranial Aneurysm

Intervention

Genetic:
• Non Interventional Study

Locations

Country	Name	City	State
France	Angers University Hospital	Angers
France	Besançon University Hospital	Besançon
France	Bordeaux University Hospital	Bordeaux
France	Henri Mondor Hospital (AP-HP)	Créteil
France	Dijon University Hospital	Dijon
France	Grenoble University Hospital	Grenoble
France	La Reunion University Hospital	La réunion
France	Kremlin-Bicêtre University Hospital (AP-HP)	Le Kremlin-Bicêtre
France	Limoges University Hospital	Limoges
France	Nancy University Hospital	Nancy
France	Nantes University Hospital	Nantes
France	La Pitié-Salpétrière University Hospital (AP-HP)	Paris
France	Lariboisière University Hospital (AP-HP)	Paris
France	Rotschild Fundation	Paris
France	Sainte Anne Hospital	Paris
France	Poitiers University Hospital	Poitiers
France	Rennes University Hospital	Rennes
France	Rouen University Hospital	Rouen
France	Toulouse University Hospital	Toulouse
France	Tours University Hospital	Tours

Sponsors (2)

Lead Sponsor	Collaborator
Nantes University Hospital	Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence or absence of genetic abnormalitie	Identification of genetic abnormalities segregant with the presence of intracranial aneurysms in the informative families recruited. Sequencing of the whole exome in a cohort of patients carriers of familial forms of intracranial aneurysms.; Analysis of blood level of the GAIA 1 protein in a large cohort of familial and sporadic carriers of intracranial aneurysms	Until one year